High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population

被引:17
|
作者
Perez, A [1 ]
Anzaldua, M [1 ]
McCormick, J [1 ]
Fisher-Hoch, S [1 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Brownsville, TX 78520 USA
关键词
disparities; hepatitis; minority; prevalence;
D O I
10.1111/j.1440-1746.2003.03277.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Texas has the highest mortality from hepatocellular carcinoma in the USA. Because end-stage liver disease mortality is most marked in the Hispanic population in the Lower Rio Grande Valley, the aim of the present paper was to estimate the prevalence of end-stage liver disease and associated factors in Brownsville. Methods: A cross-sectional study was carried out, abstracting medical charts in a community-based clinic and a hospital. A matched case-control analysis was performed. Cases had an International Classification of Disease (9th revision; ICD9) code 155.0 or 571.0-9 (primary liver cancer or chronic liver disease) recorded; age- and sex-matched controls did not have these codes. A total of 176 cases and 352 controls was collected. The main outcome measure was the prevalence and risk factors for end-stage liver disease. Results: Conservative prevalence of end-stage liver disease: 126/100 000 (386/100 000, male). Eleven out of 176 had hepatocellular carcinoma. Median age was 57 years; 72% male, 94% Hispanic. Among significant risk factors were history of hepatitis (odds ratio (OR): 19.3; 95% confidence interval (CI): 8.0-46.4), any history of alcohol use (OR: 6.6; 95%CI: 4-10.8) and history of illegal drug use (OR: 1.9; 95%CI: 1.2-2.9). Fifteen cases with no known risk factors were classified as cryptogenic cirrhosis. Only four cases out of 176 had been referred for liver transplant. Conclusions: The prevalence of end-stage liver disease in the Lower Rio Grande Valley is extremely high, with no single satisfactory explanation and with acute health disparities. Careful follow up of cryptogenic cirrhosis in this population may or may not lead to a new source of liver disease. (C) 2004 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:289 / 295
页数:7
相关论文
共 50 条
  • [11] Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease
    Antoury, Clara
    Lopez, Rocio
    Zein, Nizar
    Stoller, James K.
    Alkhouri, Naim
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (10) : 1427 - 1432
  • [12] Liver resection for hepatocellular carcinoma in patients with end-stage renal failure
    Cheng, SB
    Wu, CC
    Shu, KH
    Ho, WL
    Chen, JT
    Yeh, DC
    Liu, TJ
    P'eng, FK
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2001, 78 (04) : 241 - 246
  • [13] Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease
    Clara Antoury
    Rocio Lopez
    Nizar Zein
    James K Stoller
    Naim Alkhouri
    [J]. World Journal of Hepatology, 2015, (10) : 1427 - 1432
  • [14] Utility of Modeling End-Stage Liver Disease in Children with Chronic Liver Disease
    Kianifar, Hamidreza
    Fakhari, Sanaz Jafarzadeh
    Khalesi, Maryam
    Kiani, Mohammad Ali
    Ezzati, Atefeh
    Jafari, Seyed Ali
    [J]. INTERNATIONAL JOURNAL OF PEDIATRICS-MASHHAD, 2014, 2 (01): : 71 - 74
  • [15] Survival After Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease and Pre-Model for End-Stage Liver Disease Eras and the Independent Impact of Hepatitis C Virus
    Thuluvath, Paul J.
    Maheshwari, Anurag
    Thuluvath, Nimisha P.
    Nguyen, Geoffrey C.
    Segev, Dorry L.
    [J]. LIVER TRANSPLANTATION, 2009, 15 (07) : 754 - 762
  • [16] Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era
    Brady, Carla W.
    Smith, Alastair D.
    Stechuchak, Karen M.
    Coffman, Cynthia J.
    Tuttle-Newhall, Janet E.
    Provenzale, Dawn
    Muir, Andrew J.
    [J]. LIVER TRANSPLANTATION, 2008, 14 (02) : 228 - 234
  • [17] Role of nutrition in liver transplantation for end-stage chronic liver disease
    Stickel, Felix
    Inderbitzin, Daniel
    Candinas, Daniel
    [J]. NUTRITION REVIEWS, 2008, 66 (01) : 47 - 54
  • [18] OUTCOME OF CHRONIC LIVER DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE
    Chang, Jae Hyun
    Kim, Ae Jin
    Kim, Hyung Soo
    Ro, Han
    Jung, Ji Yong
    Lee, Hyun Hee
    Chung, Wookyung
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 252 - 253
  • [19] Management of End-Stage Liver Disease in Chronic Hepatitis B
    Tan, Hui-Hui
    Martin, Paul
    [J]. CLINICS IN LIVER DISEASE, 2010, 14 (03) : 477 - +
  • [20] Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease
    Jokinen, Mika J.
    Neuvonen, Pertti J.
    Lindgren, Leena
    Hockerstedt, Krister
    Sjovall, Jan
    Breuer, Olof
    Askemark, Yvonne
    Ahonen, Jouni
    Olkkola, Klaus T.
    [J]. ANESTHESIOLOGY, 2007, 106 (01) : 43 - 55